Q-omics provides the consensus-scored ABHD10 profile across patient tissues and cancer cell-line models. ABHD10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ABHD10 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, ABHD10 protein abundance shows 24,549 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KIRP, and PDAC as cancer lineages where ABHD10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD10 survival associations across molecular data types. ABHD10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD10 RNA expression–survival associations across cancer types. High ABHD10 expression shows unfavorable associations in SCLC, MESO and UVM, but favorable associations in KIRC, KIRP and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ABHD10 RNA expression.
This table summarizes ABHD10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ABHD10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD10 shows lower tumor expression in KIRP, THCA and KIRC and higher tumor expression in HNSC, COAD and BLCA. The KIRP box plot shows higher ABHD10 RNA expression in normal versus tumor tissue (log2 FC = −0.769, t-test p < 0.001).
This table shows molecular features associated with ABHD10 in patient tissues and cancer cell lines. In patient samples, ABHD10 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
